Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 22, 2024

BUY
$47.98 - $54.4 $35,217 - $39,929
734 Added 8.91%
8,971 $486,000
Q4 2023

Jan 10, 2024

BUY
$48.48 - $57.85 $399,329 - $476,510
8,237 New
8,237 $422,000
Q2 2023

Aug 14, 2023

SELL
$63.71 - $70.74 $22,935 - $25,466
-360 Reduced 2.88%
12,134 $775,000
Q1 2023

Apr 27, 2023

SELL
$65.71 - $74.53 $8,082 - $9,167
-123 Reduced 0.97%
12,494 $865,000
Q4 2022

Jan 19, 2023

BUY
$68.48 - $81.09 $66,425 - $78,657
970 Added 8.33%
12,617 $0
Q3 2022

Oct 27, 2022

BUY
$0.13 - $76.84 $1,514 - $894,955
11,647 New
11,647 $828,000
Q3 2021

Oct 19, 2021

SELL
$59.17 - $69.31 $811,753 - $950,863
-13,719 Closed
0 $0
Q2 2021

Jul 22, 2021

BUY
$61.91 - $67.42 $338,647 - $368,787
5,470 Added 66.31%
13,719 $917,000
Q1 2021

Apr 14, 2021

BUY
$59.34 - $66.74 $32,637 - $36,707
550 Added 7.14%
8,249 $521,000
Q4 2020

Jan 13, 2021

SELL
$57.74 - $65.43 $77,487 - $87,807
-1,342 Reduced 14.84%
7,699 $478,000
Q3 2020

Oct 14, 2020

BUY
$57.43 - $63.64 $2,814 - $3,118
49 Added 0.54%
9,041 $545,000
Q2 2020

Aug 04, 2020

BUY
$54.82 - $64.09 $104,432 - $122,091
1,905 Added 26.88%
8,992 $529,000
Q1 2020

Apr 13, 2020

BUY
$46.4 - $67.43 $27,422 - $39,851
591 Added 9.1%
7,087 $395,000
Q4 2019

Jan 23, 2020

BUY
$49.21 - $64.19 $29,378 - $38,321
597 Added 10.12%
6,496 $417,000
Q3 2019

Oct 25, 2019

BUY
$42.77 - $50.71 $39,262 - $46,551
918 Added 18.43%
5,899 $299,000
Q2 2019

Jul 23, 2019

BUY
$44.62 - $49.34 $32,884 - $36,363
737 Added 17.37%
4,981 $225,000
Q1 2019

Apr 30, 2019

BUY
$45.12 - $53.8 $191,489 - $228,327
4,244 New
4,244 $202,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $115B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Strategic Investment Advisors Portfolio

Follow Strategic Investment Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Strategic Investment Advisors , based on Form 13F filings with the SEC.

News

Stay updated on Strategic Investment Advisors with notifications on news.